SG11202009681YA - Ret inhibitor for use in treating cancer having a ret alteration - Google Patents

Ret inhibitor for use in treating cancer having a ret alteration

Info

Publication number
SG11202009681YA
SG11202009681YA SG11202009681YA SG11202009681YA SG11202009681YA SG 11202009681Y A SG11202009681Y A SG 11202009681YA SG 11202009681Y A SG11202009681Y A SG 11202009681YA SG 11202009681Y A SG11202009681Y A SG 11202009681YA SG 11202009681Y A SG11202009681Y A SG 11202009681YA
Authority
SG
Singapore
Prior art keywords
ret
treating cancer
alteration
inhibitor
ret inhibitor
Prior art date
Application number
SG11202009681YA
Inventor
Raab Erica Evans
Beni B Wolf
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of SG11202009681YA publication Critical patent/SG11202009681YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
SG11202009681YA 2018-04-03 2019-04-03 Ret inhibitor for use in treating cancer having a ret alteration SG11202009681YA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862652284P 2018-04-03 2018-04-03
US201862656297P 2018-04-11 2018-04-11
US201862657605P 2018-04-13 2018-04-13
US201862741683P 2018-10-05 2018-10-05
PCT/US2019/025655 WO2019195471A1 (en) 2018-04-03 2019-04-03 Ret inhibitor for use in treating cancer having a ret alteration

Publications (1)

Publication Number Publication Date
SG11202009681YA true SG11202009681YA (en) 2020-10-29

Family

ID=66223846

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009681YA SG11202009681YA (en) 2018-04-03 2019-04-03 Ret inhibitor for use in treating cancer having a ret alteration

Country Status (22)

Country Link
US (3) US20210100795A1 (en)
EP (2) EP3773589B1 (en)
JP (3) JP7422084B2 (en)
KR (1) KR20200139749A (en)
AU (1) AU2019247766A1 (en)
BR (1) BR112020020273A2 (en)
CA (1) CA3096043A1 (en)
CL (1) CL2020002544A1 (en)
CR (1) CR20200522A (en)
DK (1) DK3773589T3 (en)
FI (1) FI3773589T3 (en)
HR (1) HRP20240124T1 (en)
IL (1) IL277629A (en)
LT (1) LT3773589T (en)
MX (1) MX2020010417A (en)
PE (1) PE20210096A1 (en)
PL (1) PL3773589T3 (en)
PT (1) PT3773589T (en)
RS (1) RS65127B1 (en)
SG (1) SG11202009681YA (en)
SI (1) SI3773589T1 (en)
WO (1) WO2019195471A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
MX2018005528A (en) 2015-11-02 2018-11-09 Blueprint Medicines Corp Inhibitors of ret.
US20210100795A1 (en) 2018-04-03 2021-04-08 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
US11666570B2 (en) * 2019-07-11 2023-06-06 The Board Of Trustees Of The Leland Stanford Junior University Diagnosis and regulation of epidermal differentiation and cancer cell activity

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1429222A (en) 2000-02-17 2003-07-09 安姆根有限公司 Kinase inhibitors
EP1526854A1 (en) 2002-07-24 2005-05-04 University Of Cincinnati 4-4(methylpiperazin-1-ylmethyl)-n- 4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl -benzamide for treating mutated-ret kinase associated diseases
SI1696920T1 (en) 2003-12-19 2015-02-27 Plexxikon Inc. Compounds and methods for development of ret modulators
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
UA92746C2 (en) 2005-05-09 2010-12-10 Акилайон Фармасьютикалз, Инк. Thiazole compounds and methods of use
US20100047777A1 (en) 2005-05-26 2010-02-25 The Johns Hopkins University Methods for identifying mutations in coding and non-coding dna
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
EP1978958A4 (en) 2006-01-24 2009-12-02 Merck & Co Inc Ret tyrosine kinase inhibition
RU2448708C3 (en) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. ANTI-TUMOR MEANS AGAINST THYROID CANCER CANCER
US20090048214A1 (en) 2006-11-15 2009-02-19 Rigel Pharmaceuticals, Inc Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds
WO2009003136A1 (en) 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
AR067478A1 (en) 2007-07-09 2009-10-14 Astrazeneca Ab COMPOUNDS DERIVED FROM MORPHOLINE PYRIMIDINE
RU2474580C2 (en) 2007-07-19 2013-02-10 Шеринг Корпорейшн Heterocyclic amide compounds as protein kinase inhibitors
WO2009100536A1 (en) 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
EP2313091A4 (en) 2008-07-14 2012-04-04 Univ Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
CA2755953A1 (en) 2009-03-24 2010-09-30 Vertex Pharmaceuticals Incorporated Novel aminopyridine derivatives having aurora a selective inhibitory action
KR20120034726A (en) 2009-06-08 2012-04-12 아브락시스 바이오사이언스, 엘엘씨 Triazine derivatives and their therapeutical applications
CN102573484B (en) 2009-06-09 2015-07-01 加利福尼亚资本权益有限责任公司 Benzyl substituted triazine derivatives and their therapeutical applications
MX2012005023A (en) 2009-10-30 2012-06-19 Ariad Pharma Inc Methods and compositions for treating cancer.
MX2012005332A (en) 2009-11-13 2012-10-15 Oscotec Inc Kinase inhibitors.
IN2014DN01605A (en) 2011-08-04 2015-05-15 Nat Cancer Ct
EP3564261A1 (en) 2011-08-23 2019-11-06 Foundation Medicine, Inc. Kif5b-ret fusion molecules and uses thereof
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US20130096136A1 (en) 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
US10023855B2 (en) 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
CN104169260A (en) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 Novel triazone derivative
JP2015109806A (en) 2012-03-22 2015-06-18 アステラス製薬株式会社 Method for detecting new ret fused body
MX360323B (en) 2012-04-25 2018-10-29 Raqualia Pharma Inc Pyrrolopyridinone derivatives as ttx-s blockers.
CA2871540A1 (en) 2012-05-10 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
RU2019102203A (en) 2012-07-11 2019-03-05 Блюпринт Медсинс Корпорейшн FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS
CN104619841A (en) 2012-07-26 2015-05-13 日本国立癌症研究中心 Fusion gene of CEP55 gene and RET gene
WO2014039971A1 (en) 2012-09-07 2014-03-13 Exelixis, Inc. Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
AU2013321235B2 (en) 2012-09-25 2017-07-20 Chugai Seiyaku Kabushiki Kaisha RET inhibitor
US9604980B2 (en) 2012-11-07 2017-03-28 Nerviano Medical Sciences S.R.L. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
TWI629266B (en) 2012-12-28 2018-07-11 藍印藥品公司 Inhibitors of the fibroblast growth factor receptor
CA2902513A1 (en) 2013-02-25 2014-08-28 Bristol-Myers Squibb Company C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv
MX2015012286A (en) 2013-03-15 2016-05-31 Glaxosmithkline Ip Dev Ltd Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors.
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
IN2013MU00848A (en) 2013-03-19 2015-05-01 Glenmark Generics Ltd
WO2015006875A1 (en) 2013-07-18 2015-01-22 Methylgene Inc. Process for the preparation of substituted pyrimidines
CN105658814A (en) 2013-08-20 2016-06-08 日本国立癌症研究中心 New fusion gene detected in lung cancer
WO2015058129A1 (en) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
LT3057969T (en) 2013-10-17 2018-07-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
PL3395814T3 (en) 2013-10-25 2022-08-22 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
SG11201701695UA (en) 2014-09-10 2017-04-27 Glaxosmithkline Ip Dev Ltd Novel compounds as rearranged during transfection (ret) inhibitors
DK3191450T3 (en) 2014-09-10 2019-05-20 Glaxosmithkline Ip Dev Ltd PYRIDOND DERIVATIVES AS KINASE ACCESSORIES UNDER TRANSFECTION (RET)
KR102562866B1 (en) 2014-11-14 2023-08-04 네르비아노 메디칼 사이언시스 에스.알.엘. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
CN104844567B (en) 2015-04-23 2017-03-29 暨南大学 A kind of synthetic method of intermediate 1 (3 chlorine, 2 pyridine radicals) 3 bromine 1H, 5 pyrazole carboxylic acids
AU2016291676B2 (en) 2015-07-16 2020-04-30 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
KR20180048635A (en) 2015-07-24 2018-05-10 블루프린트 메디신즈 코포레이션 Compositions useful for treating disorders related to KIT and PDGFR
JP6877407B2 (en) 2015-08-26 2021-05-26 ブループリント メディシンズ コーポレイション Compounds and compositions useful for the treatment of NTRK-related disorders
CN105255927B (en) 2015-09-30 2018-07-27 温州医科大学附属第一医院 A kind of KIAA1217-RET fusions
CR20180250A (en) 2015-11-02 2018-10-01 Janssen Pharmaceutica Nv Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
BR112018008865A8 (en) 2015-11-02 2019-02-26 Five Prime Therapeutics Inc cd80 extracellular domain polypeptides and their use in cancer treatment
MX2018005528A (en) 2015-11-02 2018-11-09 Blueprint Medicines Corp Inhibitors of ret.
CN108431008A (en) 2015-11-19 2018-08-21 蓝图药品公司 It can be used for treating the compound and composition with the relevant illnesss of NTRK
WO2017100642A1 (en) 2015-12-11 2017-06-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
AR107912A1 (en) 2016-03-17 2018-06-28 Blueprint Medicines Corp RET INHIBITORS
US10576085B2 (en) 2016-04-01 2020-03-03 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
CA3020870A1 (en) 2016-04-15 2017-10-19 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
JP6943876B2 (en) 2016-04-15 2021-10-06 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ Heterocyclic compounds as RET kinase inhibitors
RS63609B1 (en) 2016-04-15 2022-10-31 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
CN110022900A (en) 2016-09-08 2019-07-16 蓝图药品公司 The combination of fibroblast growth factor receptor 4 inhibitor and cell cycle protein dependent kinase inhibitor
JP2018052878A (en) 2016-09-29 2018-04-05 第一三共株式会社 Pyridine compound
CN106749231B (en) 2016-10-09 2019-03-01 南京纳丁菲医药科技有限公司 Naphthyridine compounds and pharmaceutical composition and their application
TWI704148B (en) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US10799503B2 (en) 2016-12-01 2020-10-13 Ignyta, Inc. Methods for the treatment of cancer
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
EP3624802A1 (en) * 2017-05-15 2020-03-25 Blueprint Medicines Corporation Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity
US10934300B2 (en) 2017-06-23 2021-03-02 San Diego State University (Sdsu) Foundation Atropisomerism for enhanced kinase inhibitor selectivity
CN109180677A (en) 2017-06-30 2019-01-11 厦门大学 Substituted aryl ethers compounds, preparation method, Pharmaceutical composition and its application
EP3649260B1 (en) 2017-07-07 2022-05-11 Nipd Genetics Public Company Limited Target-enriched multiplexed parallel analysis for assessment of tumor biomarkers
CN107980784B (en) 2017-12-13 2020-05-26 中国农业大学 Application of 5-aminopyrazole compounds in regulating plant growth
DK3728271T3 (en) 2017-12-19 2022-12-19 Turning Point Therapeutics Inc Macrocyclic compounds for the treatment of diseases
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111630054B (en) 2018-01-18 2023-05-09 奥瑞生物药品公司 Substituted pyrazolo [3,4-d ] pyrimidine compounds as RET kinase inhibitors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN108341782A (en) 2018-03-30 2018-07-31 南京哈柏医药科技有限公司 The synthesis technology of 3- amino-5-methylpyrazoles
US20210100795A1 (en) 2018-04-03 2021-04-08 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
WO2020033838A2 (en) 2018-08-10 2020-02-13 Blueprint Medicines Corporation Treatment of egfr-mutant cancer
CN111362923A (en) 2020-03-25 2020-07-03 魏威 Method for preparing RET inhibitor pracetib, intermediate of pracetib and preparation method of pracetib
CN111440151A (en) 2020-03-25 2020-07-24 魏威 Method for preparing antitumor drug prasutinib
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
MX2022015022A (en) 2020-05-29 2023-03-08 Blueprint Medicines Corp Pralsetinib pharmaceutical compositions.
CN116724024A (en) 2020-12-04 2023-09-08 缆图药品公司 Process for preparing platinib

Also Published As

Publication number Publication date
EP3773589A1 (en) 2021-02-17
JP2023165937A (en) 2023-11-17
RU2020135917A (en) 2022-05-04
KR20200139749A (en) 2020-12-14
US11872192B2 (en) 2024-01-16
SI3773589T1 (en) 2024-03-29
AU2019247766A1 (en) 2020-10-15
US11273160B2 (en) 2022-03-15
EP3773589B1 (en) 2023-11-01
CL2020002544A1 (en) 2021-06-11
BR112020020273A2 (en) 2021-04-06
DK3773589T3 (en) 2024-01-29
JP2022022391A (en) 2022-02-03
US20220175773A1 (en) 2022-06-09
RS65127B1 (en) 2024-02-29
CR20200522A (en) 2021-02-17
PL3773589T3 (en) 2024-04-02
JP2021520349A (en) 2021-08-19
MX2020010417A (en) 2021-01-08
US20210100795A1 (en) 2021-04-08
US20210100799A1 (en) 2021-04-08
IL277629A (en) 2020-11-30
PE20210096A1 (en) 2021-01-12
WO2019195471A1 (en) 2019-10-10
CA3096043A1 (en) 2019-10-10
FI3773589T3 (en) 2024-02-01
HRP20240124T1 (en) 2024-04-12
EP4353317A2 (en) 2024-04-17
US20210085680A1 (en) 2021-03-25
JP7422084B2 (en) 2024-01-25
LT3773589T (en) 2024-02-12
PT3773589T (en) 2024-02-06

Similar Documents

Publication Publication Date Title
IL277783A (en) Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations
IL282663A (en) Bt1718 for use in treating cancer
IL277629A (en) Ret inhibitor for use in treating cancer having a ret alteration
IL255189B2 (en) A combination of rad1901 and a cdk4/6 inhibitor for use in treating cancer
IL284199A (en) Csf1r inhibitors for use in treating cancer
PL3371165T3 (en) A btk inhibitor for use in treating cancer
IL259479B (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
HUE053927T2 (en) Farnesyltransferase inhibitors for use in treating cancer
GB201820660D0 (en) Cancer treatments
SG11202010528XA (en) Combinations for treating cancer
IL284856A (en) A dbait molecule in combination with kinase inhibitor for the treatment of cancer
ZA202007955B (en) Ccr5 inhibitor for use in treating cancer
IL285538A (en) Combination therapies for use in treating cancer
IL283687A (en) Usp19 inhibitors for use in therapy
GB201611365D0 (en) A composition for use in treating rotavirus infection
PT3813832T (en) Compounds for use in preventing or treating cancer
EP4019634A4 (en) Compounds and methods for treating cancer
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
GB201807415D0 (en) Cancer treatments
GB201802264D0 (en) Cancer treatments